Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Multicenter, double-blind, phase III trial with adults with at least a 1-year history of migraine and two to eight migraine attacks of moderate or severe intensity per month
Primary outcome measures:
freedom from pain and freedom from the most bothersome symptom (other than pain) identified by the patient (2 hours after the dose of rimegepant or placebo was administered)
The authors concluded that treatment of a migraine attack with the oral calcitonin gene-related peptide receptor antagonist rimegepant resulted in a higher percentage of patients who were free of pain and free from their most bothersome symptoms than placebo.
…